Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies

Journal of the American Academy of Dermatology

Volumn 68, Issue 4, 2013, Pages 600-608

  Elewski, Boni E ^a   Rich, Phoebe ^b   Pollak, Richard ^c   Pariser, David M ^d   Watanabe, Shinichi ^e   Senda, Hisato ^f   Ieda, Chikara ^f   Smith, Kathleen ^g   Pillai, Radhakrishnan ^g   Ramakrishna, Tage ^h   Olin, Jason T ^h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Northwest Cutaneous Research Specialists   (United States)

^c San Antonio Podiatry Associates   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e TEIKYO UNIVERSITY   (Japan)

^f KAKEN PHARMACEUTICAL CO LTD   (Japan)

^g A Division of Valeant Pharmaceuticals North America LLC   (United States)

^h Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

efficacy; efinaconazole; onychomycosis; randomized controlled trials; safety; topical triazole antifungal

Indexed keywords

EFINACONAZOLE; POTASSIUM HYDROXIDE;

ADULT; AGED; APPLICATION SITE DERMATITIS; APPLICATION SITE REACTION; APPLICATION SITE VESICLE; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL EVALUATION; CONTACT DERMATITIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEBRIDEMENT; DISTAL LATERAL SUBUNGUAL ONYCHOMYCOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FEMALE; FOLLICULITIS; FOLLOW UP; FUNGUS CULTURE; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; INGROWN NAIL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TINEA PEDIS; TOENAIL ONYCHOMYCOSIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; ONYCHOMYCOSIS; TRIAZOLES; YOUNG ADULT;

EID: 84884211501     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.10.013     Document Type: Article

References (32)

1. R.K. Scher, and L.M. Coppa Advances in the diagnosis and treatment of onychomycosis Hosp Med 34 1998 11 20
2. J.T. Crissey Common dermatophyte infections: a simple diagnostic test and current management Postgrad Med 103 1998 191 192 197-200, 205
3. S. Kumar, and A.B. Kimball New antifungal therapies for the treatment of onychomycosis Expert Opin Investig Drugs 18 2009 727 734
4. R.K. Scher Onychomycosis: therapeutic update J Am Acad Dermatol 40 Suppl 1999 S21 S26
5. B.E. Elewski, and M.A. Charif Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions Arch Dermatol 133 1997 1172 1173 (Pubitemid 27408228)
6. L.A. Drake, D.L. Patrick, P. Fleckman, J. Andr, R. Baran, and E. Haneke The impact of onychomycosis on quality of life: development of an international onychomycosis questionnaire to measure patient quality of life J Am Acad Dermatol 41 1999 189 196 (Pubitemid 29379702)
7. R.K. Scher Onychomycosis: a significant medical disorder J Am Acad Dermatol 35 Suppl 1996 S2 S5
8. D.P. Lubeck, D.L. Patrick, P. McNulty, S.K. Fifer, and J. Birnbaum Quality of life of persons with onychomycosis Qual Life Res 2 1993 341 348 (Pubitemid 24011486)
9. L.R. Whittam, and R.J. Hay The impact of onychomycosis on quality of life Clin Exp Dermatol 22 1997 87 89 (Pubitemid 27373679)
10. A. Reich, and J.C. Szepietowski Health-related quality of life in patients with nail disorders Am J Clin Dermatol 12 2011 313 320
11. J.J. Finch, and E.M. Warshaw Toenail onychomycosis: current and future treatment options Dermatol Ther 20 2007 31 46 (Pubitemid 46568375)
12. Sporanox (itraconazole) [package insert] 2012 Janssen Pharmaceuticals Inc Titusville, NJ
13. Lamisil (terbinafine HCl) [package insert] 2012 Novartis Pharmaceuticals Corp East Hanover, NJ
14. A. Tavakkol, S. Fellman, and F. Kianifard Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in improving results in onychomycosis-concomitant Lamisil and debridement (IRON-CLAD), an open-label, randomized trial Am J Geriatr Pharmacother 4 2006 1 13
15. J.E. Arrese, and G.E. Pierard Treatment failures and relapses in onychomycosis: a stubborn clinical problem Dermatology 207 2003 255 260 (Pubitemid 37329194)
16. M.J. Darkes, L.J. Scott, and K.L. Goa Terbinafine: a review of its use in onychomycosis in adults Am J Clin Dermatol 4 2003 39 65 (Pubitemid 36082885)
17. E.M. Warshaw, D.D. Fett, H.E. Bloomfield, J.P. Grill, D.B. Nelson, and V. Quintero Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial J Am Acad Dermatol 53 2005 578 584 (Pubitemid 41399923)
18. R. Baran, B. Sigurgeirsson, D. de Berker, R. Kaufman, M. Lecha, and J. Faergemann A multicenter, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement Br J Dermatol 157 2007 149 157 (Pubitemid 46934279)
19. Fungal nail infections: diagnosis and management [editorial] Prescrire Int 18 2009 26 30
20. A.K. Gupta, and W.S. Joseph Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States J Am Podiatr Med Assoc 90 2000 495 501
21. A. Sparavigna, M. Setaro, and L. Frisenda Physical and microbiological properties of a new nail protective medical device J Plastic Dermatol 4 2008 5 12 (Pubitemid 351659267)
22. R. Baran, and A. Kaoukhov Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy J Eur Acad Dermatol Venereol 19 2005 21 29 (Pubitemid 40268136)
23. M. Lecha, I. Effendy, M. Feuilhade de Chauvin, N. Di Chiacchio, and R. Baran Treatment options-development of consensus guidelines J Eur Acad Dermatol Venereol 19 Suppl 2005 25 33
24. S. Murdan Drug delivery to the nail following topical application Int J Pharm 236 2002 1 26 (Pubitemid 34219369)
25. S.J. Baker, X. Hui, and H.I. Maibach Progress on new therapeutics for fungal nail infections Ann Rep Med Chem 40 2005 323 334
26. D. Mertin, and B.C. Lippold In vitro permeability of the human nail and of a keratin membrane from bovine hooves: influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maximum flux J Pharm Pharmacol 49 1997 30 34 (Pubitemid 27051026)
27. Y. Kobayashi, T. Komatsu, M. Sumi, S. Numajiri, M. Miyamoto, and D. Kobayashi In vitro permeation of several drugs through the human plate: relationship between physicochemical properties and nail permeability of drugs Eur J Pharm Sci 21 2004 471 477 (Pubitemid 38283920)
28. Y. Tatsumi, M. Yokoo, H. Senda, and K. Kakehi Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine Antimicrob Agents Chemother 46 2002 3797 3801 (Pubitemid 35428784)
29. W.P. Werschler, G. Bondar, and D. Armstrong Assessing treatment outcomes in toenail onychomycosis clinical trials Am J Clin Dermatol 5 2004 145 152 (Pubitemid 38901543)
30. C. De Cuyper Long-term outcomes in the treatment of toenail onychomycosis Br J Dermatol 141 1999 15 20
31. Elewski BE, Ghannoum MA, Mayser P, Gupta AK, Korting HC, Shouey RJ, et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol December doi: 10.1111/j.1468-3083.2011.04373.x. Published online December 20, 2011.
32. B.M. Piraccini, A. Sisti, and A. Tosti Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents J Am Acad Dermatol 62 2010 411 414